

## Counteracting the Disease Continuum in Hormone-Sensitive Prostate Cancer - Tweetorial #4

### References

#### Tweet 3

Francini E, Gray KP, Xie W, et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). *Prostate*. 2018;78(12):889-895. doi:10.1002/pros.23645

Gravis G, Boher JM, Chen YH, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHARTED and GETUG-AFU15 studies. *Eur Urol*. 2018;73(6):847-855. doi:10.1016/j.eururo.2018.02.001

#### Tweet 4

ERLEADA® (apalutamide) [prescribing information]. Janssen Products, LP. Approved 2018. Revised July 2021. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/210951s005lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210951s005lbl.pdf)

NUBEQA® (darolutamide) [prescribing information]. Bayer HealthCare Pharmaceuticals Inc. Approved 2019. Revised January 2021. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/212099s001lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212099s001lbl.pdf)

XTANDI® (enzalutamide) [prescribing information]. Astellas Pharma US, Inc. Approved 2012. Revised May 2021. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/213674s002lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213674s002lbl.pdf)

Ng K, Smith S, Shamash J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting. *Oncol Ther*. 2020;8(2):209-230. doi:10.1007/s40487-020-00119-z

#### Tweet 5

Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. *N Engl J Med*. 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546

#### Tweet 6

Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*. 2019;380(13):1235-1246. doi:10.1056/NEJMoa1815671

Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. *N Engl J Med*. 2020;383(11):1040-1049. doi:10.1056/NEJMoa2001342

Fizazi K, Blue I, Nowak JT. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial. *Future Oncol*. 2021;17(14):1699-1707. doi:10.2217/fon-2020-1291

#### Tweet 7

Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*. 2018;378(26):2465-2474. doi:10.1056/NEJMoa1800536

Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med*. 2020;382(23):2197-2206. doi:10.1056/NEJMoa2003892

#### **Tweet 9**

Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and metastasis-free survival in prostate cancer. *N Engl J Med*. 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546

Smith MR, Saad F, Chowdhury S, et al. Apalutamide and overall survival in prostate cancer. *Eur Urol*. 2021;79(1):150-158. doi:10.1016/j.eururo.2020.08.011

Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*. 2019;380(13):1235-1246. doi:10.1056/NEJMoa1815671

Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, Castration-resistant prostate cancer and survival with darolutamide. *N Engl J Med*. 2020;383(11):1040-1049. doi:10.1056/NEJMoa2001342

Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*. 2018;378(26):2465-2474. doi:10.1056/NEJMoa1800536

#### **Tweet 11**

Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. *N Engl J Med*. 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546

Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*. 2019;380(13):1235-1246. doi:10.1056/NEJMoa1815671

Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med*. 2018;378(26):2465-2474. doi:10.1056/NEJMoa1800536

Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. *J Clin Oncol*. 2019;37(32):2974-2986. doi:10.1200/JCO.19.00799

Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. *N Engl J Med*. 2019;381(1):13-24. doi:10.1056/NEJMoa1903307

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. *N Engl J Med*. 2019;381(2):121-131. doi:10.1056/NEJMoa1903835

#### **Tweet 12**

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. *N Engl J Med*. 2019;381(2):121-131. doi:10.1056/NEJMoa1903835

### **Tweet 13**

Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. *J Clin Oncol*. 2019;37(32):2974-2986. doi:10.1200/JCO.19.00799

Wallis CJD. ESMO 2021: Final overall survival analysis from ARCHES: a phase 3, randomized, double-blind, placebo-controlled study of enzalutamide + ADT in men with mHSPC. Accessed September 21, 2021. <https://www.urotoday.com/conference-highlights/esmo-2021/esmo-2021-prostate-cancer/132209-esmo-2021-lba25-final-overall-survival-os-analysis-from-arches-a-phase-3-randomized-double-blind-placebo-pbo-controlled-study-of-enzalutamide-enza-androgen-deprivation-therapy-adt-in-men-with-metastatic-hormone-sensitive-prostate-cancer-mhspc.html>

### **Tweet 14**

Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. *N Engl J Med*. 2019;381(1):13-24. doi:10.1056/NEJMoa1903307

Chi KN, Chowdhury S, Bjartell A, et al. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). *J Clin Oncol*. 2021;39(6\_suppl):11-11. doi:10.1200/JCO.2021.39.6\_suppl.11

### **Tweet 16**

Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. *J Clin Oncol*. 2019;37(32):2974-2986. doi:10.1200/JCO.19.00799

Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. *N Engl J Med*. 2019;381(1):13-24. doi:10.1056/NEJMoa1903307

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. *N Engl J Med*. 2019;381(2):121-131. doi:10.1056/NEJMoa1903835

Wallis CJD. ESMO 2021: final overall survival analysis from ARCHES: A phase 3, randomized, double-blind, placebo-controlled study of enzalutamide + ADT in men with mHSPC. Accessed September 21, 2021. <https://www.urotoday.com/conference-highlights/esmo-2021/esmo-2021-prostate-cancer/132209-esmo-2021-lba25-final-overall-survival-os-analysis-from-arches-a-phase-3-randomized-double-blind-placebo-pbo-controlled-study-of-enzalutamide-enza-androgen-deprivation-therapy-adt-in-men-with-metastatic-hormone-sensitive-prostate-cancer-mhspc.html>

Chi KN, Chowdhury S, Bjartell A, et al. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). *J Clin Oncol*. 2021;39(6\_suppl):11-11. doi:10.1200/JCO.2021.39.6\_suppl.11

Agarwal N, McQuarrie K, Bjartell A, et al. Health-related quality of life after apalutamide treatment in

patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. *Lancet Oncol.* 2019;20(11):1518-1530. doi:10.1016/S1470-2045(19)30620-5

## Glossary

ABI, abiraterone  
ADT, androgen deprivation therapy  
AE, adverse event  
ALT, alanine transaminase  
ANC, absolute neutrophil count  
APA, apalutamide  
AR, androgen receptor  
AST, aspartate transaminase  
CAD, coronary artery disease  
CI, confidence interval  
CrCl, creatinine clearance  
DAR, darolutamide  
DOC, docetaxel  
ENZ, enzalutamide  
Hb, hemoglobin  
HCP, healthcare provider  
HR, hazard ratio  
HSPC, hormone-sensitive prostate cancer  
HTN, hypertension  
HV, high volume  
LHRHa, luteinizing hormone–releasing hormone analog  
LN, lymph node  
LV, low volume  
MACE, major adverse cardiovascular events  
Mets, metastases  
Metach, metachronous  
MFS, metastasis-free survival  
mF-up, median follow-up  
mCRPC, metastatic castration-resistant prostate cancer  
mHSPC, metastatic hormone-sensitive prostate cancer  
mOS, median overall survival  
MO, nonmetastatic  
M1, metastatic  
NE, not estimable  
nmCRPC, nonmetastatic castration-resistant prostate cancer  
NR, not reached  
OS, overall survival  
PBO, placebo  
PCa, prostate cancer  
PFS, progression-free survival  
PSA, prostate-specific antigen  
PSADT, prostate-specific antigen doubling time  
QOL, quality of life

RT, radiation therapy  
rPFS, radiographic progression-free survival  
SOC, standard of care  
SRE, skeletal-related events  
SSE, symptomatic skeletal event  
TBL, total bilirubin  
TT, time to  
TTM, time to metastasis  
TTR, time to resistance  
ULN, upper limit of normal  
w/, with  
WCC, white cell count